ARICEPT better tolerated than Exelon in patients with mild to moderate Alzheime...( 394 million days of patient use worldw...),Health

Eisai Co., Ltd., and Pfizer Inc are committed to a collaboration dedicated to advances in Alzheimers therapy. These studies were funded by Eisai and Pfizer Inc.

_________________________

Physicians Satisfaction Questionnaire: When surveyed on overall satisfaction with ARICEPT for each patient, physicians who participated in the study reported very satisfied for 46.4% of patients; satisfied for 48.2% of patients; neither satisfied nor dissatisfied for 1.8% of patients; dissatisfied for 0.0% of patients; "very dissatisfied" for 3.6% of patients.

Physicians Satisfaction Questionnaire: When surveyed on overall satisfaction with Exelon for each patient, physicians who participated in the study reported "very satisfied" for 18.9% of patients; satisfied for 49.1% of patients; "neither satisfied nor dissatisfied" for 17% of patients; "dissatisfied" for 11.3% of patients; "very dissatisfied" for 3.8% of patients.

Approved product labeling for ARICEPT is the same with regard to dosage and administration in the EU and the USA. Approved product labeling for Exelon is the same with regard to dosage and administration in the EU and the USA.

These treatment-emergent adverse events occurred in greater than or equal to 5% of patients and at least twice as frequently in either treatment group (all causalities).

'"/>

Contact: Celeste Torello, Pfizer Inc.
212-733-6471
Porter Novelli
26-Sep-2000